Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC)

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1643-1648

  Zeamari, S ^a   Floot, B ^a   Van Der Vange, N ^a   Stewart, F A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Cisplatin; HIPEC; Hyperthermia; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CISPLATIN;

ABDOMINAL CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CANCER CHEMOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG PENETRATION; FEMALE; HYPERTHERMIA; HYPERTHERMIC INTRAPERITONEAL CHEMOPERFUSION; HYPERTHERMIC THERAPY; INTRAOPERATIVE PERIOD; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RAT;

ABSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; INJECTIONS, INTRAPERITONEAL; INTRAOPERATIVE PERIOD; KIDNEY; LIVER; MAXIMUM TOLERATED DOSE; NEOPLASM TRANSPLANTATION; PERFUSION; PERITONEAL NEOPLASMS; PERITONEUM; RATS; TISSUE DISTRIBUTION;

EID: 0038237922     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Swedish Rectal Cancer Trial: Improved survival with pre-operative radiotherapy in resectable rectal cancer. N Engl J Med 336: 980-7, 1997.
2. Abulafi AM and Williams NS: Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 81(1): 7-19, 1994.
3. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW and McVie JG: Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49(12): 3380-4, 1989.
4. Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D, Smals O, Gonzalez-Gonzalez D and McVie JG: Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27(4): 472-7, 1991.
5. Spratt JS, Adcock RA, Muskovin M, Sherrill W and McKeown J: Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2): 256-60, 1980.
6. Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, Dalton RR, Ettinghausen SE, Jacquet P, Jelinek J, Koslowe P, Kurman, RJ, Shmookler B, Stephens AD, Steves MA, Stuart OA, White S, Zahn CM and Zoetmulder FA: Pseudomyxoma peritonei syndrome. Adv Surg 30: 233-80, 1996.
7. Sugarbaker PH, Zhu BW, Sese, GB and Shmookler B: Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 36(4): 323-9, 1993.
8. Witkamp AJ, De Bree E, Kaag MM, Boot H, Beijnen JH, Van Slooten GW, Van Coevorden F and Zoetmulder FA: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37(8): 979-84, 2001.
9. van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, Ten Bokkel Huinink WW, Beijnen JH, Bartelink H and Begg AC: Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34(1): 148-54, 1998.
10. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D and Sugarbaker PH: Heated Intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 55(2): 130-8, 1998.
11. Zedeck MS and Sternberg SS: A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate. J Natl Cancer Inst 53(5): 1419-21, 1974.
12. van Warmerdam LJ, van Tellingen O, Bokkel Huinink WW, Rodenhuis S, Maes RA and Bijnen JH: Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements? Ther Drug Monit 17(5): 465-70, 1995.
13. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, and McVie JG: Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25(6): 389-94, 1990.
14. Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu, PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E and Figg WD: Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 39(4): 394-401, 1999.
15. Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK and Alexander HR: Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 3(3): 174-9, 1997.
16. Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA and Lagasse LD: Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67(12): 1085-92, 1983.
17. Stephens AD, Belliveau JF and Sugarbaker PH: Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis. Cancer Treat Res 81: 15-30, 1996.
18. Pestieau SR, Stuart OA, Chang D, Jacquet P and Sugarbaker PH: Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 84(6): 706-11, 1998.
19. Jacquet P, Averbach A, Stuart OA, Chang D and Sugarbaker PH: Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 41(2): 147-54, 1998.
20. Page RL, Lee J, Riviere JE, Dodge RK, Thrall DE and Dewhirst MW: Absence of whole body hyperthermia effect on cisplatin distribution in spontaneous canine tumors. Int J Radiat Oncol Biol Phys 32(4): 1097-102, 1995.
21. Sminia P, Los G, Hendriks JJ, van Vugt MJ, Haveman J and Gonzalez Gonzalez D: The influence of hyperthermia on the uptake of cisplatin in the rat cervical spinal cord. Eur J Cancer 28A(6-7): 1139-43, 1992.
22. Ratto GB, Civalleri D, Esposito M, Spessa E, Alloisio A, De Cian F and Vannozzi MO: Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 117(4): 759-65, 1999.